



**Meeting to commence at 9.30 am on Tuesday, 13<sup>th</sup> October 2020**

**(via Zoom)**

**AGENDA**

- |    |  |                                    |
|----|--|------------------------------------|
| 1. | <b>Welcome and introduction</b>  | <b>Enclosure</b>                   |
| 2. | <b>Apologies</b>   |                                    |
| 3. | <b>Declarations of interest</b>  |                                    |
| 4. | <b>Minutes of the previous meeting</b>   | <b>1/AWMSG/1020</b>                |
| 5. | <b>Chairman's verbal report</b>  |                                    |
| 6. | <b>AWMSG work programme - updates</b>  |                                    |
|    | <ul style="list-style-type: none"><li>- <b>Medicine optimisation framework proposal</b></li><li>- <b>Communication and engagement strategy</b></li><li>- <b>Implementation and supporting best practice</b></li></ul>  |                                    |
| 7. | <b>AWMSG alignment with NICE Guidance in NHS Wales</b>   | <b>2/AWMSG/1020</b><br>(to follow) |
| 8. | <b>Appraisal: Full submission</b>  |                                    |
|    | <b>meropenem/vaborbactam (Vaborem®)</b> for the treatment of complicated urinary tract infection including pyelonephritis, complicated intra-abdominal infection, hospital-acquired pneumonia including ventilator associated pneumonia in adults and for the treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above. Meropenem/vaborbactam is also indicated for the treatment of infections due to Gram-negative organisms in adults with limited treatment options | <b>3/AWMSG/1020</b><br>Enclosures  |

**Date of next meeting: Wednesday 11<sup>th</sup> November 2020 commencing 9.30 am**